Last reviewed · How we verify
NCT06824688
Single-port Versus Multi-port Robotic Surgery for Rectal Cancer
NA trial testing Single-port robotic total mesorectal excision in Rectal Cancer Patients in 40 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 23 October 2024 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Single-port robotic total mesorectal excision
- Multi-port robotic total mesorectal excision
Conditions studied
- Rectal Cancer Patients — all drugs for Rectal Cancer Patients →
- Robotic Surgical Procedures — all drugs for Robotic Surgical Procedures →
Sponsor
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Who can join
18 and older, any sex, with Rectal Cancer Patients or Robotic Surgical Procedures. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Single-port versus multi-port robotic surgery for rectal cancer
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06824688
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Rectal Cancer Patients
Currently open trials in the same condition.
- NCT07522294 — Optimization and Standardization of Single-Port Robotic Transanal Minimally Invasive Surgery for Rectal Tumor Excision · NA · active not recruiting
- NCT07198165 — SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC · Phase 2 · recruiting
- NCT07337811 — Selective Total Mesorectal Excision Based on Intra-Operative Frozen Section From Local Excision in Rectal Cancer Undergo · NA · recruiting
- NCT06647680 — Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01） · Phase 2 · recruiting
- NCT06911684 — Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC · Phase 2 · recruiting
Other Daping Hospital and the Research Institute of Surgery of the Third Military Medical University trials
Trials by the same sponsor.
- NCT07468630 — Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma · Phase 2 · recruiting
- NCT07467590 — Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Stud · Phase 2 · not yet recruiting
- NCT07459192 — Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors · not yet recruiting
- NCT07459179 — Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognit · not yet recruiting
- NCT07459205 — Clinical Application of 68Ga-1A12 PET in Fibrosis-related Diseases · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06824688 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Last refreshed: 19 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06824688.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing